ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Tobacco Control and Prevention Saved 795,000 Lives Between 1975-2000, Study Shows

March 30, 2012

NIH Limits Increases In Competing Renewals To Biomedical Deflator

August 30, 1991

In Brief: Survey Expected To Stimulate Surge Of Interest In Finding Etiological Factors In U .S. County-By-County Variations

April 19, 1974

Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication

November 25, 2011

Feinstein Reintroduces New National Cancer Act

June 13, 2003

NCI Seeks Changes In CIS Funding Plan With Next Recompetition

April 24, 1987